Calypso Biotech: Clinical progression and 8M funding for Calypso Biotech

Following the launch of its phase I clinical trials for lead candidate CALY-002, Merck Serono spin-off, Calypso Biotech, has secured €8 million in a Series A extension round, bringing the total capital raised to €28 million. The funds will accelerate clinical developments.